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Summary
Background Vulvar Paget disease (VPD) is extremely rare and thought to be associated
with other malignancies.
Objectives To evaluate the risk of developing breast, intestinal and urological malig-
nancies in patients with VPD compared with the general population, and in particu-
lar to focus on the risk of malignancy in patients with cutaneous noninvasive VPD.
Methods Data on the oncological history of patients with any type of VPD between
2000 and 2015 were obtained from PALGA, a nationwide archive containing all
pathology reports in the Netherlands. Follow-up data and a control group from
the general population were obtained from the Netherlands Cancer Registry.
After correction for age and calendar year at time of diagnosis, standardized inci-
dence ratios (SIRs) for the first 3 years after VPD diagnosis were estimated with
95% confidence intervals (CIs).
Results We identified 199 patients with a first diagnosis of VPD [164 noninvasive,
35 (micro)invasive] between 2000 and 2015. The SIR of developing an associ-
ated malignancy in the first 3 years after diagnosis was 467 (95% CI 266–
764). This was due mainly to the high incidence of intestinal malignancies
among patients with secondary VPD. Subgroup analysis for cutaneous noninva-
sive VPD did not reveal a significantly increased risk for associated malignancies:
SIR 208 (95% CI 076–462).
Conclusions Of our patients with VPD, 769% were diagnosed with cutaneous non-
invasive VPD, and this group has no increased risk for developing malignancies
of the breast, intestine or urological tract. Our study suggests that routine screen-
ing for these malignancies in patients diagnosed with cutaneous noninvasive VPD
may not be necessary.
What’s already known about this topic?
• In the past, all types of vulvar Paget disease (VPD) were associated with breast,
intestinal and urological malignancies.
What does this study add?
• This study challenges the long-held assumption that primary cutaneous noninvasive
VPD is associated with these malignancies.
• This population-based study showed no increased risk of malignancies of the
breast, intestine or urological tract in patients with cutaneous noninvasive VPD.
• There is no evidence to support routine screening for underlying malignancies in
patients with cutaneous noninvasive VPD.
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Vulvar Paget disease (VPD) is a rare skin disorder, most com-
monly seen in postmenopausal white women.1 VPD causes
itching or burning erythematosquamous plaques and is diag-
nosed when typical Paget cells are seen in the epidermis. VPD
can be classified according to origin and invasion: it can be
primary and of cutaneous origin (type 1) or secondary to an
intestinal (type 2) or urological (type 3) malignancy.2 Most
cases of primary disease (i.e. cutaneous) are noninvasive (type
1a). Cutaneous VPD can invade through the basal membrane
(type 1b) or be seen in conjunction with a vulvar adenocarci-
noma (type 1c). The difference between primary and sec-
ondary VPD cannot be made on histopathological assessment
alone.3 The aetiology and origin of Paget cells remain
unknown.1
VPD has been considered to be associated with malignan-
cies of the breast, intestinal tract and urological tract.4,5
Some consider VPD secondary to intestinal or urological
malignancies a pagetoid spread rather than a separate entity.
Therefore, some consider primary noninvasive VPD to be
the only ‘true’ VPD, and secondary VPD a ‘pagetoid phe-
nomenon’.6–9
In the late 19th century, skin lesions like the nipple
ulceration associated with breast cancer became known as
extramammary Paget disease (EMPD).10–12 The histological
characteristics of EMPD resemble those of mammary Paget
disease, raising the suspicion of a comparable pathogene-
sis.13 The term VPD is used for EMPD specifically localized
on female genital skin. In 1975, Friedrich et al. analysed
11 published articles, including 78 patients with VPD, of
whom 14 (18%) were diagnosed with breast cancer
around VPD diagnosis.4 The authors concluded that screen-
ing for breast cancer should be standard care in patients
with VPD.
In 1985, Chanda summarized 197 cases of EMPD in a liter-
ature review.5 Of these patients, 128 had VPD. Simultaneous
occurrence of a malignancy and VPD was reported in 12% of
cases, and overall 29% of the patients were reported to have
had a malignancy of either the breast or gynaecological,
intestinal or urological tracts. The true association between
these so-called ‘associated’ malignancies and EMPD was ques-
tioned, as most malignancies were not diagnosed at the same
time as EMPD, and the two diseases were not shown to have a
parallel course. However, Chanda concluded that clinicians
should consider a search for malignancies of the gastrointesti-
nal tract in cases of perianal EMPD, or for genitourinary
malignancies in genital EMPD. Ever since, the assumed associa-
tion between VPD and malignancies has been generally
accepted. Nowadays, international guidelines advise that
women with VPD should be screened for associated malignan-
cies.14,15 However, the extent and timing of screening and the
preferred diagnostics are not exemplified.
Our recent analysis of publications describing 10 or more
patients with VPD suggests that breast, intestinal and urologi-
cal malignancies in patients with VPD are rare: 32% had a
history of breast cancer, 22% of intestinal cancer and 39% of
urological cancer.1
The aim of this study was to estimate the risk of developing
breast, intestinal or urological malignancies in all patients with
(non)invasive VPD in comparison with the general population,
and moreover to evaluate whether all patients with VPD
should be routinely screened for malignancies.
Patients and methods
Patient selection
The PALGA database, a nationwide network and registry of
histo-and cytopathology in the Netherlands with national
coverage since 1991, was searched for all cases of VPD and
vulvar adenocarcinomas. All cases with a first diagnosis of
VPD, noninvasive and invasive, between 1 January 2000
and 31 December 2014 were included. We excluded cases
of adnexal gland tumours, mammary-like gland tumours or
vulvar adenocarcinomas without evidence of VPD. Patients
with vulvar localization of an intestinal or urological malig-
nancy were also excluded.
We recorded the type of VPD as reported in the pathol-
ogy report: primary VPD (of cutaneous origin), which can
be distinguished with the following immunohistochemical
(IHC) profile: CK7+ CK20; secondary VPD of intestinal
origin, which can be distinguished with the IHC profile
CK7 CK20+ CDx2+; and secondary VPD of urological ori-
gin with the IHC profile CK7 CK20+ and uroplakin-III+.
Pathology reports that concluded with ‘vulvar Paget dis-
ease’ but in which IHC results were not available were
reported as VPD not otherwise specified (NOS); these were
assumed to be primary VPD, as this is the most common
type.1 Follow-up data were retrieved via the Netherlands
Cancer Registry (NCR), which has national coverage since
1989 and registers all malignancies in the Netherlands. If
follow-up data were not available from the NCR, we used
the date of the last pathology report as the last date of
follow-up.
Associated malignancies
Patients with VPD diagnosed with associated malignancies
were identified from the pathology reports, as were the age
at diagnosis of the associated malignancy and the date of
diagnosis.
All invasive breast, intestinal or urological tumours were
defined as being potentially associated with VPD. Besides inva-
sive tumours, ductal carcinoma in situ of the breast was also
included, because it is considered to be a malignancy. Intesti-
nal malignancies included tumours of the colon, rectum, rec-
tosigmoid junction and anus. Urological malignancies
included tumours of the kidney, ureter, bladder and urethra.
All women with histological confirmation of one or more
of the aforementioned tumours between 2000 and 2015 were
selected from the NCR. The total number of women living in
the Netherlands by age category and calendar year was
obtained from Statistics Netherlands.
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Statistical analysis
The incidence of associated malignancies in women with VPD
was compared with the incidence of these malignancies in
women from the general population. The expected incidence
was extracted from data from the NCR and population data
from Statistics Netherlands. Risks were stratified by age and
calendar-year diagnosis of malignancy. The standardized inci-
dence ratio (SIR) was estimated as the observed incidence of
an associated malignancy in women with VPD divided by the
expected incidence in women from the general population.
SIRs were estimated until 36 months after VPD diagnosis, as
we assumed that malignancies diagnosed within 36 months
after VPD diagnosis might have already been present, possibly
as a premalignancy, at the time of VPD diagnosis. Furthermore,
this time frame ensured a reasonable sample size for the study
cohort. We performed subgroup analyses for cases reported as
primary noninvasive VPD only. Statistical models were based
on a Poisson distribution using person-time at risk as an offset.
Person-time at risk was calculated as the time from the date
of first VPD diagnosis to the date of first histological confirma-
tion of the associated malignancy of interest, date of death or
date of last follow-up, whichever came first. Follow-up data
were available up to 1 January 2015. Analyses were performed
using Stata/SE 13.0 (StataCorp, College Station, TX, U.S.A.).
SIRs and their 95% confidence intervals (CIs) were based on
the Mid-P exact test16 and were calculated using the OpenEpi
Standardized Mortality Ratio Calculator (OpenEpi version
3.01).17 The figures were designed using Microsoft Office
Excel 2007 and Visio 2007.
Results
Population
In total, 199 women with a first diagnosis of VPD in the Nether-
lands (around 17 million inhabitants) between 2000 and 2015
were identified from the pathology reports. Noninvasive VPD
was diagnosed in 164 patients (824%), microinvasive VPD in
12 (60%) and invasive VPD in 23 (116%). An overview of the
types of VPD per diagnosis is presented in Table 1. We consid-
ered NOS as primary cutaneous VPD in further analyses. The
median age at diagnosis was 74 years (range 40–97), and did
not differ between patients with noninvasive and (micro)inva-
sive disease (P = 084). The median follow-up time of all
patients was 36 months (range 0–182) after VPD diagnosis.
Associated malignancies
Of all patients, 27 (136%) were diagnosed with breast cancer,
17 (85%) with an intestinal malignancy and nine (45%) with
a urological malignancy before, simultaneously with or after the
diagnosis of VPD (Table S1; see Supporting Information). Three
patients (15%) had a history of two associated malignancies.
Eighteen of the 27 patients (67%) with breast cancer
received this diagnosis before they were diagnosed with VPD;
the median time difference was 102 months (range 3–213).
Three of these 18 patients were diagnosed with breast cancer
within 3–6 months prior to the VPD diagnosis, which was
primary noninvasive in all three. Eight of the 27 patients
(30%) were diagnosed with breast cancer after their VPD
diagnosis, and the median time difference between diagnoses
was 46 months (range 1–116). Two of these eight patients
were diagnosed with breast cancer within 2 months after the
VPD diagnosis, which was primary noninvasive in both. It is
uncertain whether these malignancies were detected with the
VPD screening protocol. The time of breast cancer diagnosis
in relation to VPD diagnosis was unknown for one patient.
In six (35%) of the 17 patients with intestinal malignancies
and VPD, the intestinal malignancy was diagnosed before they
were diagnosed with VPD, with a median time difference of
201 months (range 96–272). Two of the 17 patients (12%)
were diagnosed with the intestinal malignancy and VPD simul-
taneously, both having type 2 VPD. Nine patients (53%) were
diagnosed with an intestinal malignancy at a median time dif-
ference of 16 months (range 1–90) after VPD diagnosis. Four
of these nine patients (44%) had a urological malignancy
before the VPD diagnosis, with a median time difference of
152 months (range 103–249). Urological malignancies were
diagnosed after VPD in the other five patients (56%), after a
median of 50 months (range 11–147).
Figure 1(a) shows the time differences between diagnoses
of VPD and the associated malignancies for all patients, and
Figure 1(b) shows the time differences between VPD diagnosis
and the associated malignancies for the subgroup of primary
noninvasive VPD. The time difference between VPD diagnosis
and urological malignancies, for example, was between
250 months prior to and 150 months after VPD diagnosis.
Risk of developing an associated malignancy after any
type of vulvar Paget disease diagnosis
The cumulative risk of developing any of the associated malig-
nancies within 36 months after diagnosis of any type of VPD
was increased, with an SIR of 467 (95% CI 266–764). This
increased risk was based mainly on the statistically signifi-
cantly increased risks of developing an intestinal malignancy,
SIR 818 (95% CI 399–150), and a urological malignancy,
SIR 667 (95% CI 119–220). The SIR for developing a breast
Table 1 Overview of types of vulvar Paget disease (VPD) per
diagnosis
Noninvasive
VPD
(Micro)invasive
VPD Total
NOS 133 (668) 25 (125) 158 (794)
Type 1, cutaneous 20 (101) 8 (40) 28 (141)
Type 2, intestinal 8 (40) 2 (10) 10 (50)
Type 3, urological 3 (15) 0 3 (15)
Total 164 (824) 35 (176) 199 (100)
Values are n (%). NOS, not otherwise specified.
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malignancy was not statistically significant: SIR 200 (95% CI
051–544) (Table 2).
Risk of developing an associated malignancy after
diagnosis of primary noninvasive vulvar Paget disease
Table 3 shows the analysis restricted to patients with primary
noninvasive VPD. The SIR for developing any of the associated
malignancies was 208 (95% CI 076–462). The SIR for
breast cancer was 250 (95% CI 064–680), the SIR for
intestinal malignancies was 111 (95% CI 006–548) and the
–300 –250 –200 –150 –100 –50 0 50 100 150 200
0 50 100 150 200
Time interval between diagnosis of VPD (n=199) and associated malignancy in months
Breast malignancy, n=26
Intesnal malignancy, n=17
Urological malignancy, n=9
–300 –250 –200 –150 –100 –50
Time interval between diagnosis of primary noninvasive VPD (n=153) and associated malignancy in months
Breast malignancy, n=24
Intesnal malignancy, n=7
Urological malignancy, n=6
(a)
(b)
Fig 1. (a) Time interval between diagnosis of vulvar Paget disease (VPD) (all types) and associated malignancy. (b) Time interval between
diagnosis of noninvasive primary VPD and associated malignancy.
Table 2 Risk of developing an associated malignancy within 3 years
after diagnosis, all types of vulvar Paget disease (VPD)
Year
after
VPD Observed Expected SIR 95% CI
Cumulative
risk
1 9 12
2 4 10
3 1 08
14 30 467* 266–764
Breast cancer 1 2 06
2 1 05
3 0 04
3 15 200 051–544
Intestinal
malignancy
1 6 04
2 2 04
3 1 03
9 11 818* 399–150
Urological
malignancy
1 1 01
2 1 01
3 0 01
2 03 667* 112–220
SIR, standardized incidence ratio; CI, confidence interval. *Statis-
tically significant SIR.
Table 3 Risk of developing an associated malignancy, non-invasive
primary VPD
Year
after VPD Obs Exp SIR 95% CI
1 3 10
2 2 08
3 0 06
Cumulative risk 5 24 208 076-462
1 2 05
2 1 04
3 0 03
Breast cancer 3 12 250 064-680
1 0 04
2 1 03
3 0 02
Intestinal
malignancy
1 09 111 006-548
1 1 01
2 0 01
3 0 01
Urological
malignancy
1 03 333 017-1644
Risk of developing an associated malignancy within 3 years after
diagnosis with non-invasive primary VPD. VPD: vulvar Paget dis-
ease. Obs: observed cases per year and in total. Exp: expected
cases per year and in total. SIR: standardized incidence ratio.
95%CI: 95% confidence interval. Statistically significant SIRs are
marked with an asterisk (*).
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SIR for urological malignancies was 333 (95% CI 017–164).
None of these SIRs was statistically significant.
Discussion
This is the first population-based study investigating the inci-
dence of possibly associated malignancies in patients with VPD.
The risk of developing an associated malignancy within 3 years
after VPD diagnosis of any subtype is significantly increased
compared with the general Dutch female population. However,
subgroup analysis of the patients with primary noninvasive
VPD showed no significantly increased risk of developing one
of the associated malignancies. Therefore, there is no evidence
for a routine screening programme for these malignancies in
patients diagnosed with primary noninvasive VPD.
All patients who were diagnosed with an intestinal or uro-
logical malignancy around the time of VPD diagnosis were
diagnosed with secondary VPD (type 2 or 3). In patients with
primary (i.e. cutaneous), noninvasive VPD the time interval
between VPD diagnosis and the diagnosis of the associated
malignancy varied greatly. We were therefore unable to iden-
tify a clear parallel course between primary noninvasive VPD
Fig 2. Flowchart for the work-up of newly diagnosed patients with vulvar Paget disease (VPD). Vulvar mapping ideally consists of several punch
biopsies taken from all suspicious lesions; histological slides are reviewed under the microscope and additional immunohistochemistry (IHC) is
performed on all of the slides. VSCC, vulvar squamous cell carcinoma.
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and the so-called associated malignancies. This raises the ques-
tion of a consistent or comparable aetiology.
The main limitation of our study is the large group of cases
labelled NOS. Our data were collected from two nationwide
databases. This means it was not viable to review the
histopathological samples and perform additional IHC studies
to define the origin. We relied on the assessment of multiple
pathologists throughout the country, which reflects daily prac-
tice. We assumed patients with VPD NOS to have noninvasive
cutaneous VPD. The distribution of the different types of VPD
in our study cohort resembles the distribution reported in the
literature.1 It is possible that this assumption caused us to
overestimate the incidence of associated malignancies in this
subgroup, as we might have included patients with VPD sec-
ondary to another malignancy.
Several studies have reported that perianal localization of
EMPD is a risk factor for intestinal or anal malignancies, and
recent literature indicates that the location of the skin lesion
influences the disease-specific survival.18,19 Nonetheless, it is
uncertain how the skin lesion and the intestinal malignancy
are related to each other in cases of secondary VPD. A recent
epidemiological study by Karam and Dorigo reported a higher
risk of intestinal malignancies in EMPD.20 They reported an
SIR for any malignancy of 147 (95% CI 117–184), but did
not find a statistically significantly increased risk for breast
cancer (SIR 141, 95% CI 085–220), anorectal and colorectal
malignancies (SIR 164, 95% CI 090–276), bladder malig-
nancies (SIR 239, 95% CI 065–613) or kidney/pelvic
malignancies (SIR 093, 95% CI 002–521). However, this
study included male and female patients with invasive disease.
If the intestinal malignancy grows continuously to the epider-
mis, the question may be raised whether the EMPD lesion
should be considered an expansion of the tumour rather than
a separate entity. This holds true especially in cases with inva-
sive disease, as it is impossible to determine which lesion
came first.
As suggested above, differentiation between the subtypes of
VPD (primary cutaneous, or secondary to an intestinal or uro-
logical malignancy) may be of great importance for the risk of
developing other malignancies. However, currently there are
no clear guidelines for this differentiation. It is generally
accepted that the IHC profile of Paget cells can help to charac-
terize different subtypes. As stated above, the cutaneous phe-
notype is determined by a CK7+ CK20 profile, the intestinal
phenotype by CK7 CK20+ CDx2+ and the urological pheno-
type by CK7 CK20+ and uroplakin-III+. These are the main
markers that have been used to distinguish primary from sec-
ondary VPD for almost two decades.3,21–23 There are no stud-
ies assessing the sensitivity and specificity of IHC analysis in
differentiating the different subtypes of VPD, and the reliabil-
ity of several other IHC stains can be discussed. An example is
GATA3, which is reported to be sensitive, and also a potential
pitfall, in recognizing VPD secondary to urothelial malignan-
cies.24,25
Acknowledging this limitation, we assessed the risk of not
screening for malignancy in those patients with a cutaneous
IHC profile. Based on our data, refraining from additional
screening for malignancies where IHC analysis shows a cuta-
neous profile would have missed five patients over 15 years in
the Netherlands, a country of around 17 million inhabitants.
However, there are national screening programmes for both
breast and intestinal malignancies in which most patients
would be screened anyway. In case IHC analysis shows an
intestinal or urological origin for the VPD lesion, a directed
surveillance for the specific malignancies can be performed.
To assist clinicians in the work-up of newly diagnosed patients
with VPD, we suggest a work-up according to the flowchart
in Figure 2. Even though our results indicate that there may
be no association between cutaneous VPD and underlying
malignancy, screening may still be warranted depending on
the clinical context.
Our study population contains 15 years of national data and
is the first to focus on primary noninvasive VPD. We were not
able to match all cases reported in the PALGA database to
patients registered in the NCR to obtain follow-up data. We
therefore used the date of the last pathology report as the last
date of follow-up. This may shorten follow-up times and
therefore reduce the sample size: at 36 months after VPD
diagnosis the cohort consisted of 101 patients. With a small
cohort the number of expected events (i.e. the development
of one of the associated malignancies), based on the incidence
in the general age- and calendar-year-corrected population,
would be smaller than 1 patient per year. This causes the SIR
to be disproportionately high for those years in which an
associated malignancy was diagnosed.
For inclusion in the study we required that associated
malignancies had to be histologically confirmed. It is possible
that we missed cases of associated malignancies that were
diagnosed via clinical examination or imaging, without histol-
ogy. However, this is corrected by including only histologi-
cally confirmed malignancies in our background file of the
general population.
The main goal of this study was to estimate the risk of
developing associated malignancies in patients with VPD and
to evaluate the need for screening for these malignancies.
Looking at all patients with any type of VPD, we find that the
risk of developing an associated malignancy is increased. VPD
can be a sign of an internal malignancy, and may be a valu-
able cutaneous sign prompting earlier diagnosis. A diagnosis
of secondary VPD, with an IHC phenotype favouring noncuta-
neous origin, should prompt a search for internal malignancy
above and beyond physical examination.
The data in this study suggest promisingly that there is no
statistically significant increase in cancer diagnosed in the first
3 years after primary noninvasive VPD compared with the
general population. This may assist clinicians in reassuring and
allaying the concerns of patients with noninvasive VPD. Reas-
suringly, most of these patients are often at an age where they
are offered screening for bowel, breast and cervical cancer.
Therefore, our main conclusion is that there is no evidence
for the need for routine screening in patients diagnosed with
primary noninvasive VPD.
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